Does My District Need a Mobile Stroke Unit?
NEJM 385:971-981,1043, Lees, K.R., 2021
Telemedicine in Prehospital Stroke Evaluation and Thrombolysis
JAMA Neurol 73:162-168, Itrat, A.,et al, 2016
Cost-Effectiveness of Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
Neurol 86:1053-1059, Aronsson, M.,et al, 2016
Implementing a Mobile Stroke Unit Program in the United States
JAMA Neurol 72:229-234, Rajan, S.,et al, 2015
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke
Stroke 46:2591-2598, Ganesalingam, J.,et al, 2015
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
The Cost-Effectiveness of Telestroke in the Treatment of Acute Ischemic Stroke
Neurol 77:1590-1598, Nelson, R.E.,et al, 2011
Cost-Effectiveness of Multimodal CT for Evaluation Acute Stroke
Neurol 75:1678-1685, Young,K.C.,et al, 2010
Cost-Effectiveness of Patient Selection Using Penumbral-Based MRI for Intravenous Thrombolysis
Stroke 40:1710-1720, Earnshaw,S.R.,et al, 2009
Telemedicine Versus Telephone for Remote Emergency Stroke Consultations: A Critically Appraised Topic
The Neurologist 15:163-166, Capampngan,D.J.,et al, 2009
Is it Time for Neurohospitalists?
Neurol 70:1282-1288, Freeman,W.D.,et al, 2008
Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke
Stroke 38:85-89, Ehlers,L.,et al, 2007
Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada
Storke 38:1952-1955,1732, Yip,T.R. &Demaerschalk,B.M., 2007
Long-Term Outcome After Thrombolysis in Telemedical Stroke Care
Neurol 69:898-903,819, Schwab,S.,et al, 2007
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Stroke 36:2500-2503, Demaerschalk,B.M. &Yip,T.R., 2005
Is Hospitalization After TIA Cost-Effective on the Basis of Treatment With tPA?
Neurol 65:1799-1801, Nguyen-Huynh,M.N. &Johnson,S.C., 2005
Surgical Decompression of Patients with Large Middle Cerebral Artery Infarcts is Effective
Stroke 34:2304-2305,2307, Schwab,S.&Hacke,W., 2003
Surgical Decopression of Patients With Large Middle Cerebral Artery Infarcts is Effective:Not Proven
Stroke 34:2305-2306,2307, Brown,M.M., 2003
Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Comparison of Diffusion-Weighted MRI and CT in Acute Stroke
Neurol 54:1557-1561,1548,1549,1552, Lansberg,M.G.,et al, 2000
Treatment of Acute Ischemic Stroke
NEJM 343:710-722, Brott, T. & Bogousslavsky, J., 2000
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Treatment and Secondary Prevention of Stroke:Evidence, Costs, and Effects on Individuals and Populations
Lancet 354:1457-1463, Hankey,G.J.&Warlow,C.P., 1999
Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke, Emergency Management of Stroke (EMS) Bridging Trial
Stroke 30:2598-2605, Lewandowski,C.A.,et al, 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based Approach
Stroke 29:1544-1549, Grond,M.,et al, 1998
Cost-Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Neurol 50:883-890, Fagan,S.C.,et al, 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
When is Thrombolysis Justified in Patients with Acute Stroke? A Bioethical Perspective
Stroke 28:214-218, Furlan,A.J.&Kanoti,G., 1997
HIV-1 Protease Inhibitors
JAMA 227:145-149, Deeks,S.J.,et al, 1997
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
Cost-effectiveness of Emergency Intraarterial Intracerebral Thrombolysis:A Pilot Study
AJNR 16:1987-1993, 19941995., Lanzieri,C.F.,et al, 1995
The Effect of Comb Oral Lysine Acetylsalicylate & Metoclopramide Compared w/Oral Sumatriptan for Migraine
Lancet 346:923-926, Tfelt-Hansen,P.,et al, 1995
Stroke:The Way Things Really Are
Stroke 25:1290-1294, Scheinberg,P., 1994
The Dilemma of Delirium:Clin & Research Contro in Dx Eval in Hosp Elderly Pts
Am J Med 97:278-288, Inouye,S.K., 1994